ImmunoCellular Therapeutics, Ltd. 4

4 · ImmunoCellular Therapeutics, Ltd. · Filed Nov 27, 2013

Form 4

Period: 2013-11-25

Director

Transactions

Exercise/Conversion
Stock Option (right to buy)
2013-11-25−30,301→ 19,699 total
Exercise: $1.35Exp: 2014-06-27→ Common Stock (30,301 underlying)
Exercise/Conversion
Stock Option (right to buy)
2013-11-26−19,699→ 0 total
Exercise: $1.35Exp: 2014-06-27→ Common Stock (19,699 underlying)
Exercise/Conversion
Stock Option (right to buy)
2013-11-26−8,301→ 0 total
Exercise: $0.95Exp: 2016-09-13→ Common Stock (8,301 underlying)
Exercise/Conversion
Common Stock
2013-11-25$1.30/sh+25,000$32,500→ 35,000 total
Sale
Common Stock
2013-11-25$3.50/sh−30,301$106,096→ 10,000 total
Exercise/Conversion
Common Stock
2013-11-26$1.35/sh+19,699$26,594→ 29,699 total
Exercise/Conversion
Common Stock
2013-11-26$0.95/sh+8,301$7,886→ 18,301 total
Exercise/Conversion
Stock Option (right to buy)
2013-11-25−25,000→ 0 total
Exercise: $1.30Exp: 2014-11-04→ Common Stock (25,000 underlying)
Exercise/Conversion
Common Stock
2013-11-25$1.35/sh+30,301$40,906→ 40,301 total
Sale
Common Stock
2013-11-26$3.86/sh−19,699$76,011→ 10,000 total
Sale
Common Stock
2013-11-26$3.86/sh−8,301$32,030→ 10,000 total
Sale
Common Stock
2013-11-25$3.02/sh−25,000$75,448→ 10,000 total

Footnotes (2)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
[F2]Fully vested.

Documents

2 files